Press Release: European Medicines Agency recommends approval of sofosbuvir for the treatment of chronic hepatitis C

Author (Corporate)
Series Title
Series Details EMA/717004/2013 (22.11.13)
Publication Date 22/11/2013
Content Type

The European Medicines Agency's Committee for Medicinal Products for Human use (CHMP), in November 2013, recommended granting a marketing authorisation for Sovaldi (sofosbuvir), for use 'in combination with other medicinal products for the treatment of chronic (long-term) hepatitis C in adults'.
Source Link http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001970.jsp&mid=WC0b01ac058004d5c1
Related Links
EMA: Press Release; EMA/717004/2013 (22.11.13): European Medicines Agency recommends approval of sofosbuvir for the treatment of chronic hepatitis C http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/11/WC500155469.pdf
EMA: Press Release: EMA/719859/2013 (22.11.13): European Medicines Agency advises on compassionate use of daclatasvir http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/11/WC500155474.pdf
Subject Categories
Countries / Regions